Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for Vistagen Therapeutics (VTGN) over the last 12 years, with Q4 2025 value amounting to $26000.0.

  • Vistagen Therapeutics' Capital Expenditures changed N/A to $26000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $48000.0, marking a year-over-year decrease of 5200.0%. This contributed to the annual value of $29000.0 for FY2024, which is 9450.76% down from last year.
  • Latest data reveals that Vistagen Therapeutics reported Capital Expenditures of $26000.0 as of Q4 2025.
  • Over the past 5 years, Vistagen Therapeutics' Capital Expenditures peaked at $528000.0 during Q1 2023, and registered a low of -$200300.0 during Q1 2022.
  • In the last 5 years, Vistagen Therapeutics' Capital Expenditures had a median value of $28000.0 in 2024 and averaged $51964.7.
  • In the last 5 years, Vistagen Therapeutics' Capital Expenditures tumbled by 19940000.0% in 2022 and then surged by 36360.46% in 2023.
  • Over the past 5 years, Vistagen Therapeutics' Capital Expenditures (Quarter) stood at -$100.0 in 2021, then crashed by 199400.0% to -$199500.0 in 2022, then soared by 116.04% to $32000.0 in 2023, then fell by 12.5% to $28000.0 in 2024, then fell by 7.14% to $26000.0 in 2025.
  • Its Capital Expenditures stands at $26000.0 for Q4 2025, versus $60000.0 for Q3 2025 and $65000.0 for Q2 2025.